Switzerland· 69498002

Apremilast-Mepha

A apremilast product containing apremilastum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 18 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat B (Swissmedic)ATC L04AA32

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedApremilast-MephaATCL04AA32REGISTER NO.69498002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Apremilast is registered in 18 of 19 countries.

Countries holding a registration under ATC L04AA32 (apremilast), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 10 of them publish a price we can compare per daily dose

Apremilast · ATC L04AA32

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of apremilast costs, country by country.

Normalised to the WHO defined daily dose (60 mg), the median price runs from $13.92 in Switzerland to $51.51 in Italy — a ×3.7 gap.

  • Switzerland: $13.92 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Apremilast · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • IT Italy$51.51
  • CZ Czechia$51.22
  • FR France$22.59
  • CH Switzerland$13.92
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
apremilastum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L04AA32
ATC class
Apremilast
Defined daily dose
60 mg, O
Swissmedic category
B
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680694980029
    Blist 56 Stk
    CHF 323.2

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

82 interactions on record for apremilast.

Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Apremilast · interactions on record

82 records

  • 11 severe
  • 69 moderate
  • 2 minor

Most severe, free to view

  • RifampicinJ04AB02severe
  • MitotaneL01XX23severe
  • EnzalutamideL02BB04severe
  • ApalutamideL02BB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Apremilast in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All apremilast products

Authorised across Europe · EMA

The same active substance is authorised in 31 EEA countries. Names it is sold under:

  • Austria · Apremilast +pharma, Apremilast Devatis
  • Belgium · Apremilast Eg, Apremilast Hcs
  • Bulgaria · Тивлемак
  • Cyprus · Apremilast Ebewe, Apremilast Sandoz
  • Czechia · Apremilast +pharma, Apremilast Belupo
  • Germany · Apremilast, Apremilast 089pharm
  • Denmark · Apremilast Devatis, Apremilast Stada
  • Estonia · Apremilast Krka, Apremilast Stada
  • Spain · Apremilast, Apremilast Aurovitas Spain
  • Finland · Apremilast Avansor, Apremilast Bioglan
  • France · Apremilast Arrow, Apremilast Biogaran
  • United Kingdom (Northern Ireland) · Apremilast, Apremilast Amarox
  • Greece · Afimax, Apremilast Anabiosis
  • Croatia · Aperzyx, Apremilast Belupo
  • Hungary · Apremilast Kezdőcsomag Stada, Apremilast Krka
  • Ireland · Apremilast 30mg Tablets, Apremilast Aurobindo
  • Iceland · Apremilast Accord, Apremilast Aristo
  • Italy · Apremilast Day Zero, Apremilast Dr. Reddy’s
  • Liechtenstein · Apremilast Accord
  • Lithuania · Apremilast Krka, Apremilast Stada
  • Luxembourg · Apremilast Eg
  • Latvia · Apremilast Krka, Apremilast Stada
  • Malta · Apremilast, Apremilast Clonmel
  • Netherlands · Apremilast Amarox, Apremilast Devatis
  • Norway · Apremilast Accord, Apremilast Devatis
  • Poland · Apremilast Aristo, Apremilast Farmaprojects
  • Portugal · Apremilaste Humanis
  • Romania · Apremilast Stada
  • Sweden · Apremilast Anabiosis, Apremilast Avansor
  • Slovenia · Apremilast Belupo, Apremilast Elpen
  • Slovakia · Apremilast Belupo, Apremilast Hcs

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e82cd38d-ddbf-410b-906a-b4b2522e0385
GET /v1/drugs/e82cd38d-ddbf-410b-906a-b4b2522e0385?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "apremilastum 30 mg",
  "valid_from": "2025-09-01",
  "limitations": "[{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong>F&uuml;r alle verg&uuml;tungspflichtigen Indikationen gilt:<br></strong>APREMILAST-MEPHA darf nicht in Kombination mit Biologika zu Lasten der OKP verordnet werden.<br><br>Die Verschreibung von APREMILAST-MEPHA f&uuml;r die folgenden Behandlungen kann nur durch Fach&auml;rzte der Dermatologie oder Rheumatologie oder dermatologische bzw. rheumatologische Universit&auml;tskliniken/Polikliniken erfolgen</p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"21988.XX\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-09-01\",\"validTo\":null},{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong>Aktive Psoriasis-Arthritis</strong><br>Behandlung erwachsener Patienten mit aktiver Psoriasis-Arthritis als Monotherapie oder in Kombination mit DMARDs (z. Bsp. Methotrexat), wenn das Ansprechen auf eine vorhergehende Therapie mit krankheitsmodifizierenden Antirheumatika (DMARDs) unzureichend gewesen ist.</p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"21988.01\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-09-01\",\"validTo\":null},{\"description\":\"<!DOCTYPE html>\\n<html>\\n<head></head>\\n<body>\\n<p><strong>Schwere Plaque Psoriasis</strong><br>Behandlung erwachsener Patienten mit schwerer Plaque-Psoriasis, bei denen eine Phototherapie oder eine der folgenden konventionellen systemischen Therapien (Ciclosporin, Methotrexat, Acitretin) keinen therapeutischen Erfolg gezeigt haben. Falls nach 24 Wochen kein therapeutischer Erfolg eingetreten ist, ist die Behandlung abzubrechen.</p>\\n</body>\\n</html>\",\"costApproval\":null,\"indication\":\"21988.02\",\"isNew\":true,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2026-09-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 30 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2025-09-01",
  "self_retention_pct": 10
}

See everything about apremilast.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.